胸腺五肽联合TP方案治疗晚期非小细胞肺癌的成本-效果分析  

Cost-effectiveness Analysis of Thymopentin Combined with TP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：李玉平[1] 张晓庆[1] 胡苹[1] 李一倩[1] 倪健[2] 

机构地区：[1]同济大学附属上海市肺科医院药剂科,上海200433 [2]同济大学附属上海市肺科医院肿瘤科,上海200433

出　　处：《中国药房》2013年第4期329-332,共4页China Pharmacy

基　　金：上海市药学会上海医院药学科研基金资助项目(No.2009-YY-01-18)

摘　　要：目的:观察并比较胸腺五肽联合多西他赛+顺铂(TP)化疗与单纯化疗治疗晚期非小细胞肺癌(NSCLC)的成本-效果。方法:选择我院NSCLC患者214例,按照化疗方案分为4组:国产TP组(A组,58例)、进口TP组(B组,54例)、胸腺五肽+国产TP组(C组,52例)、胸腺五肽+进口TP组(D组,50例),14d为一个周期,均连用2个周期,观察4组患者临床效果、不良反应并进行成本-效果分析。结果:治疗后,4组化疗疗效比较,差异无统计学意义(P>0.05);4组组内治疗前、后生活质量评分均显著提高,差异有统计学意义(P<0.05);A、B组治疗后CD3、CD4及CD4/CD8比值均显著提高(P<0.05);4组白细胞下降发生率比较差异有统计学意义(P<0.05);以成本最低的A组方案作为参照,每增加1%有效率所需追加的成本以C组方案最低,药物费用下降10%时,增加相同效果所需成本仍以C组方案最低。结论:4组化疗方案治疗晚期NSCLC疗效、安全性相似,但胸腺五肽+国产TP治疗晚期NSCLC成本-效果较优。OBJECTIVE：To observe and compare the cost-effectiveness of thymopentin combined with TP regimen vs.chemotherapy alone for advanced non-small cell 1ung cancer（NSCLC）.METHODS：214 NSCLC patients were collected from our hospital.They were divided into 4 groups according to chemotherapy regime：domestic TP group（group A,58 cases）,imported TP group（group B,54 cases）,thymopentin＋domestic TP group（group C,52 cases）and thymopentin＋ imported TP group（group D,50 cases）.A treatment course lasted for 14 days,and they were treated for 2 cycles.Clinical effect and adverse drug reaction were observed in 4 groups,and cost-effectiveness analysis was conducted.RESULTS：After treatment,there was no statistical significant difference in therapeutic efficacies among 4 groups（P0.05）;Karnofsky score of 4 groups were improved significantly after treatment,and there was statistical difference（P0.05）.After therapy,CD3,CD4 and the ratio of CD4/CD8 in group A and B were significantly improved（P0.05）;there was statistical significance in the incidence of leucocytopenia among 4 groups（P 0.05）;compared with A group,the additional cost of group C was the lowest with effective rate increased by 1%;the cost of group C was the lowest for achieving the same effect when drug cost decreased by 10%.CONCLUSION：Chemotherapy regimen of 4 groups show similar efficacy and safety in the treatment of advanced NSCLC.Thymopentin＋domestic TP is the optimal scheme for NSCLC.

关 键 词：胸腺五肽 多西他赛 非小细胞肺癌 成本-效果分析 

分 类 号：R956[医药卫生—药学]